↓ Skip to main content

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation

Overview of attention for article published in Frontiers in immunology, August 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
16 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
Published in
Frontiers in immunology, August 2022
DOI 10.3389/fimmu.2022.960412
Pubmed ID
Authors

Isabel Martínez-Romera, Víctor Galán-Gómez, Berta González-Martínez, Pilar Guerra García, Sonsoles San Román Pacheco, Dolores Corral Sánchez, Yasmina Mozo del Castillo, David Bueno Sánchez, Luisa Sisinni, Alba González Guerrero, Serafin Castellano Dámaso, Elena Sánchez Zapardiel, Beatriz Ruz Caracuel, Antonio Balas Pérez, Antonio Pérez-Martínez

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 19%
Unspecified 2 13%
Student > Bachelor 2 13%
Student > Master 2 13%
Student > Doctoral Student 1 6%
Other 1 6%
Unknown 5 31%
Readers by discipline Count As %
Medicine and Dentistry 5 31%
Unspecified 2 13%
Biochemistry, Genetics and Molecular Biology 1 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Nursing and Health Professions 1 6%
Other 1 6%
Unknown 5 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2022.
All research outputs
#3,951,877
of 26,178,577 outputs
Outputs from Frontiers in immunology
#4,549
of 32,859 outputs
Outputs of similar age
#80,047
of 436,927 outputs
Outputs of similar age from Frontiers in immunology
#218
of 2,047 outputs
Altmetric has tracked 26,178,577 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,859 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,927 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 2,047 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.